Lung Cancer

Pathophysiology

Approximately 80% to 85% of lung cancers are non-small cell lung cancer (NSCLC), mainly manifesting as nonsquamous cell carcinoma (eg, adenocarcinoma and large cell carcinoma) or squamous cell carcinoma.1

Landscape

Lung cancer is one of the most common cancers worldwide.2 Progress has been made with anti–PD-1/PD-L1 inhibitor research.3-6 Areas of research include identification of treatment options for patients with squamous cell carcinoma since some mutations that are targetable with currently approved agents are rare in patients with squamous histology.7-11 Therapies under investigation include the use of targeted approaches, eg, signal transduction inhibitors, immune modulation, chimeric antigen receptor (CAR) T cell therapy, antibody drug conjugates, and epigenetic modulation through DNA hypomethylating agents and histone deacetylase inhibitors.12-14

Read more Collapse

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

View Molecular Pathways

In Our Pipeline

Choose filters to find specific trials in the BMS pipeline.

Filter trials by:

STATUS

PHASE

trials
View Lung Cancer Trials Through Our Pipeline

To search for clinical trials with other recruiting statuses,
please visit bolderscience.com.

Clinical trial information is sourced from ClinicalTrials.gov. Information is updated manually as clinical trials are published. The efficacy and safety of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

References

  1. American Cancer Society. http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf.pdf
  2. International Agency for Research on Cancer. World Health Organization. GLOBOCAN 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
  3. Opdivo (nivolumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2019.
  4. Keytruda (pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2019.
  5. Tecentriq (atezolizumab) [package insert]. South San Francisco, CA: Genentech, Inc; 2016.
  6. Imfinzi (durvalumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.
  7. Avastin (bevacizumab) [package insert]. South San Francisco, CA: Genentech, Inc; 2014.
  8. Avastin (bevacizumab) [summary of product characteristics]. Grenzach-Wyhlen, Germany: Roche Pharma AG; 2015.
  9. Alimta (pemetrexed) [package insert]. Indianapolis, IN: Lilly USA, LLC; 2013.
  10. Alimta (pemetrexed) [summary of product characteristics]. Fegersheim, France: Lilly France SAS; 2014.
  11. Paik PK, et al. J Clin Oncol. 2012;30(suppl) [abstract 7505].
  12. Zaman A, Bivona TG. Ann Transl Med. 2018;6:160. PMID: 29911108
  13. Dholaria B, et al. J Hematol Oncol. 2016;9:138. PMID: 27938382
  14. Ansari J, et al. Transl Lung Cancer Res. 2016;5:155-171. PMID: 27186511